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Imaging mass spectrometry is currently receiving a significant amount of attention in the mass
spectrometric community. It offers the potential of direct examination of biomolecular patterns
from cells and tissue. This makes it a seemingly ideal tool for biomedical diagnostics and
molecular histology. It is able to generate beautiful molecular images from a large variety of
surfaces, ranging from cancer tissue sections to polished cross sections from old-master
paintings. What are the parameters that define and control the implications, challenges,
opportunities, and (im)possibilities associated with the application of imaging MS to biomed-
ical tissue studies. Is this just another technological hype or does it really offer the hope to gain
new insights in molecular processes in living tissue? In this critical insight this question is
addressed through the discussion of a number of aspects of MS imaging technology and
sample preparation that strongly determine the outcome of imaging MS experiments. (J Am
Soc Mass Spectrom 2009, 20, 1006–1014) © 2009 Published by Elsevier Inc. on behalf of
American Society for Mass SpectrometryIf a picture speaks a thousand words then an imag-ing mass spectrometry experiment is a book withmany chapters. Each page of the book contains
different descriptive pictures of an independent molec-
ular distribution on a complex surface such as a his-
topathological tissue section. In this way new molecular
anatomical atlases can be created. This opens the door
for molecular histology in biomedicine. Historically
there are many different applications of imaging MS [1].
In the field of semiconductor production and research it
has been one of the tools of choice for surface contam-
ination analysis. It has been used in the study of aging
of old-master paintings, polymeric surfaces, geological
samples, and forensic research. The biggest driver for
the recent rapid developments is the prospect of the
application of imaging MS directly on biological tissue
sections [2–6] and single cells and the full integration
within the proteomics field. For that reason the discus-
sion in this presentation will be restricted to the impli-
cations, challenges, opportunities, and (im)possibilities
associated with the application of imaging MS of bio-
medical tissue.
The advantages of using a mass spectrometer for
molecular imaging in the discovery phase of any bio-
medical experiment are wide-ranging in scope. It elim-
inates the need for labeling because the molecular mass
is used as an endogenous label. This leaves the biomol-
ecules of interest functionally unmodified. In this way it
removes the interference of potential fluorescent labels
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try also allows the detection of post-translational mod-
ifications (PTMs) given that these generally involve
mass changes. Often it is not possible to generate
antibodies that allow the (labeled) visualization of the
PTM distribution directly in tissue. With a mass spec-
trometer it is “easy” to see the location of the mass
change. An additional advantage is that mass spectrom-
etry provides multiplexed information from a surface
since for each peak in the mass spectrum an image can
be generated. Many commercial instruments now offer
imaging capabilities and, as a result, the field is evolv-
ing rapidly and many new groups are now getting
involved with this exciting technology.
Imaging MS is a booming field, as illustrated by the
rapidly increasing number of publications as sketched
in Figure 1. The potential of the technology is clear: it
offers a new tool to trace various compounds and
metabolites. Yet as with many new technologies there is
a risk that expectations are raised that will be difficult to
meet because of several technological obstacles. That
raises the question: hype or hope?
The hope of biomedical imaging mass spectrometry
can be summarized in a single sentence: It is the hope that
we will be able to cure neurodegenerative diseases, cancer,
and aggressive viral infections through better fundamental
understanding of the morphology and molecular pathology of
the diseases. Imaging mass spectrometry has the power
to provide that molecular insight. In that light it can be
considered a discovery tool. It is claimed to be capable
of discovering new molecular distributions that when
compared to existing immunohistochemical images
can indicate which other molecules are involved in a
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question arises: “Is it there yet?”
Application Areas
Historically, imaging mass spectrometry is applied in
material sciences where Secondary Ion Mass Spectrom-
etry (SIMS) is used to examine the distribution of
inorganic species on surfaces. SIMS is also used to
examine biological surfaces, but never made a major
impact in biological research [7]. LAMMA was one of
the earlier laser-based imaging MS technologies, but its
application remained restricted to material science,
small molecules, and—again—inorganic species. Appli-
cations for relevant biomedical studies were not possi-
ble until the conception of desorption and ionization
technologies such as matrix-assisted laser desorption/
ionization (MALDI) that enabled the analysis of intact
biomolecular ions. Approximately 10 years after the
first MALDI paper [8] the field of biomolecular imaging
mass spectrometry started to emerge [2]. With new
sample-handling technologies, innovations in mass
spectrometers in this new field influenced other imag-
ing MS applications, as can be seen in Figure 1. To
address the question “hype or hope?” it is imperative to
explore what the most strongly growing application
areas for imaging mass spectrometry are. Three bio-
medical application areas fit that criterion: proteomics,
lipidomics, and pharmacology. The illustration in Fig-
ure 2 shows three images from these application areas.
Imaging MS in proteomics is often advertised for the
visualization of peptide and protein biomarker patterns
specific to disease. Comparative image analysis of
healthy and diseased tissue sections targets the visual-
ization of aberrant molecular pathology. Imaging in
lipidomics can be used to visualize intact lipid molec-
ular distributions and determine head group identity,
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Figure 1. Development of imaging mass spectrometry publica-
tion numbers since 1998. Results based on an ISI keyword search
using imaging mass spectrometry and MALDI imaging.acyl chain lengths, and degrees of unsaturation onsingle-cell surfaces. Pharmaceutical research uses imag-
ing MS complementary to whole body autoradiography
in both research and the developmental phase of new
drugs [9]. MS imaging is particularly interesting be-
cause it has the potential to image simultaneously the
drugs and their metabolites. MALDI MS imaging offers
the possibility not only of examining and tracking
drug metabolism in whole animal sections, but also of
following polymer substrate degradation and drug
release.
Proteomics, lipidomics, and pharmacokinetics incite
the biggest interest in the life science community be-
cause combined, they can be used to assess the effects
of drugs on proteome and lipidome. This sketches a
powerful potential and raises expectations of the tech-
nology. The question is whether the technology is
already mature enough to fulfill this potential. A num-
ber of critical elements exist in any imaging MS (IMS)
workflow that can strongly affect the outcome of an
experiment. In this critical insight we will describe a
number of issues that are currently addressed and
discussed within the imaging MS community. Sample
preparation, ion suppression, sensitivity, and data anal-
ysis are aspects of imaging mass spectrometry that
merit critical evaluation. Together they strongly influ-
ence the outcome and relevance of an imaging experi-
ment. New technologies are continuously added to the
imaging MS toolbox to address these issues. There is a
strong need to combine these novel imaging tools with
existing molecular imaging techniques such as MRI and
immunohistochemistry to make IMS an accepted mo-
lecular pathology technique in biomedical research.
Figure 2. Main biomedical aapplication areas of imaging mass
spectrometry, proteomics, lipidomics, and drugs and metabolite
imaging. (a) The distribution of a number of endogenous neu-
ropeptides on a rat brain section. (b) The distribution of lipids of
the surface of single neuroblastoma cells. (c) The distribution of a
metabolite in the kidney of a whole body cross section of a rat.
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Technological developments have long driven imaging
MS. Relatively recently a set of new tools have been
added to the MS imaging toolbox. MALDI-time-of-
flight (ToF) MS-based imaging has become a routine
tool from the technological perspective. Its application
is limited only by sample quality and reproducible
preparation protocols that we will discuss later. In this
section three new instrumentation developments are
discussed that can be seen as breakthrough technolo-
gies in IMS defining the state of the art. Each of them is
aimed at improving the data quality and information
content resulting from an imaging MS experiment. The
first development is the microscope mode approach to
improve speed and spatial resolution of an IMS mea-
surement. The second instrumental platform that will
further imaging MS is Fourier-transform ion cyclotron
resonance (FT-ICR)-MS that addresses the lack of mass
spectral resolution and mass accuracy combined with
tandem MS (MS/MS) identification possibilities. The
last emerging technology is the use of ion mobility
separation in IMS experiments that introduces gas-
phase separation capabilities to distinguish isobaric
compounds based on their different molecular confor-
mations. Each of these new developments has clear
potential to increase the information content of imaging
MS experiments. They will also result in even larger
datasets than those obtained with current MALDI-ToF
imaging. In the subsections below we will discuss these
three new developments individually.
1. Spatial Resolution: Microscope Mode Imaging MS
Spatial resolution has long been a limiting factor. Con-
ventional approaches in MALDI-ToF imaging are based
on the microprobe approach. There a laser or ion beam
is focused to a small spot from which a single mass
spectrum is acquired. An image is generated by raster-
ing this spot in a predefined manner over the surface,
probing the surface and collecting spectra at different
locations. The spatial resolution is determined by the
size of the probe beam. In commercial instruments the
physical size of the laser spot is limited to around 10
m. On commercial instruments most experiments are
performed with a laser spot size between 50 and 250
m. This choice is determined by sensitivity and the
time required to complete an experiment. Special con-
focal type objectives [10] can reduce the spot size to 1
m, although there is substantial debate as to whether
the laser threshold fluence required for the use of these
small spots with MALDI is not too high for intact
molecular analysis directly from tissue. Initial expe-
riments have shown the capability to acquire high-
resolution images of smaller species. An alternate ap-
proach to increase spatial resolution using conventional
MALDI-ToF instruments is the oversampling approach
introduced by the Sweedler group [11]. In their ap-proach the incremental movement of the laser probe
spot is smaller than the spot diameter. After all sample
has been consumed at the first spot each incremental
step delivers information from a much smaller area. As
a result the spatial resolution can be increased. The
limited MS/MS possibilities and the total sample con-
sumption are two drawbacks of this approach.
The achievable spatial resolution in imaging MS can
also be increased through the use of microscope mode
imaging mass spectrometry [12]. This method uses
high-quality ion optics that provide an astigmatic pro-
jection of ions generated at the surface on the detector of
the ToF-MS. This implies that the spatial distribution of
the ions stays intact while they are flying through the
mass spectrometer, resulting in traveling molecular
images. A detector that can simultaneously acquire
arrival time and arrival position (x, y, and tTOF) of the
ions at the end of the flight tube can directly acquire
these molecular images, essentially taking molecular
snapshots. The spatial resolution is defined by the
quality of the ion optics, the ion optical magnification,
and the pixel size on the detector. The implementation
described in Luxembourg et al. [12] delivers pixel sizes
that are 600 nm by diameter. An added advantage is
that a larger field of view in acquired simultaneously as
a result of direct multiplexed detection of many pixels
at once. This dramatically increases the throughput of
high spatial resolution imaging MS. A 200-m diameter
area can be analyzed with a 600-nm pixel size in 1 s
without fully depleting the surface. This implies that
the surface can be reanalyzed with an additional tech-
nique, either optically or with another imaging MS step.
As an example: Figure 2a was measured in the micro-
scope mode in 2.5 h and covered an area of 1.5 2.5 cm
with 600-nm pixels and a resolving power (determined
by the number of pixels required to resolve a feature) of
2–4 m. The total dataset size was 200 Gbyte. This
approach has one other advantage. It also allows the
use of desorption and ionization beams that are difficult
to focus to submicron spot sizes for high spatial reso-
lution analysis. An example is the use of IR-MALDI
imaging, with resolutions below the diffraction limit of
the optical system used. It allows IR imaging with
identical spatial resolution as UV-based MALDI imag-
ing, even though the wavelength is an order of magni-
tude longer [13].
Irrespective of which method is used to increase the
spatial resolution, sensitivity and spatial resolution re-
main intimately coupled. Only few molecules are avail-
able for desorption and ionization if the spatial resolu-
tion would increase to 10 nm or below. This implies a
need for single-ion detection MS imaging. It is obvious
that we are not there yet, although new developments
in detection technology are moving this field forward.
The other limiting factor for high spatial resolution
analysis concerns the enormous dataset sizes generated
when large areas need to be imaged. Imaging a whole
rat section (16 4-cm area) with 100-nm pixels would
result 6.4  1011 spectra. This would result in a single
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the spectra are reduced to 1 kbyte. This is clearly not
achievable with current technology.
2. Spectral Resolution: FT-ICR MS Imaging
High-quality images alone are not enough. Compound
identification accuracy is equally as important as—if
not more important than—spatial resolution. MS imag-
ing methods such as TOF-SIMS and microscope mode
MALDI-TOF offer high spatial resolution but lack the
mass resolving power and mass accuracy needed for
the identification of all observed peaks. MALDI-TOF
MS provides a good compromise between spatial reso-
lution and mass resolving power; however, MSn exper-
iments can be difficult. FT-ICR MS allows spatial re-
solution similar to that of conventional microprobe
MALDI-TOF, with the high mass accuracy and ultra-
high mass resolving power necessary for unequivocal
identification of measured masses and use of different
MSn techniques (e.g., sustained off-resonance irradia-
tion collision-induced dissociation [SORI-CID], infrared
multiphoton dissociation [IRMPD], and electron cap-
ture dissociation [ECD]) [14]. Figure 3 demonstrates the
need for ultra-high mass resolving power for identifi-
cation of species on a rat brain tissue [15]. Insets a and
d in Figure 3 show a selected region from summed
spectra for two halves of a rat brain; inset a was
analyzed by FT-ICR MS and inset d by TOF-MS. FT-ICR
identifies multiple peaks over themass range, whereas the
TOF-MS cannot resolve even the nominal masses. More-
over, inset b shows that the three species resolved at m/z
1293 show unique spatial distributions in the rat brain and
that the lower mass resolving power of TOF-MS (see inset
e) yields a combined spatial distribution.
The power of FT-ICRMS to image isobaric species on
tissue has been demonstrated [15–19]. In addition, each
of these studies used MS/MS to positively identify
peaks from the mass spectrum. Although FT-ICR MS
offers the benefits of high mass accuracy, ultra-high
mass resolving power, and multiple MS/MS tech-
niques, it also has inherent disadvantages. Time of
analysis becomes an issue for FT-ICR MS at very high
mass resolving powers, especially if the experiment is
done serially. Interlaced experiments—that is, external
accumulation during the excite/detect events—help to
shorten experiment times. Similarly, data size is also of
concern at very high mass resolving powers, even more
so than for typical TOF-MS imaging experiments. Fi-
nally, the singly charged ions predominantly produced
by MALDI hamper ECD MS/MS fragmentation and
also limit the mass range for FT-ICR MS. The analytical
capabilities for FT-ICR MS would be greatly enhanced
when moving to stronger magnetic fields. Imaging
mass spectrometry in particular would benefit with
either enhanced resolution (at the expense of through-
put) and speed of analysis (at the expense of mass
resolution) because the transients become shorter at thesame resolution as the ion cyclotron frequencies in-
crease with magnetic field.
3. Conformational Resolution: Ion Mobility in MS
Imaging
The combination of ion mobility [20, 21] in a MALDI-TOF
instrument is one of the breakthrough technologies for
mass spectrometry imaging and its application. Ion mo-
bility mass spectrometry (IM-MS) is described as a two-
dimensional gas-phase separation technique using them/z
ratio and conformational separation in a drift cell. The ion
mobility drift cell region is an electric field and gas-filled
region that separatesmolecules such as nucleotides, lipids,
peptides, and proteins by their velocity based on their
collision cross section. Inside the drift cell region, ions
acquire an average drift velocity based on their collision
cross section to charge ratio, thus allowing the separation
of molecules according to their conformation. Since the
commercialization of different ion mobility cells, a large
number of applications have been described in the study
of complex mixtures. The two-dimensional separation
allows the separation of isobaric compounds, offering new
interesting applications. MALDI ion mobility mass spec-
trometry allows classically top-down protein sequencing
and structural determination of noncovalent complexes.
When combined with imagingmass spectrometry it offers
the possibility of directly indentifying protein conformers,
as well as isobaric and low-abundance species in complex
mixtures such as tissue sections. As such, IM-MS can be
directly used for biological and clinical proteomics studies
by MALDI imaging analysis. Because of the separation of
isobaric lipids and peptides, a larger number of molecules
have been detected and identified directly on-tissue sam-
ple [22, 23]. The use of ionmobility is suitable for the direct
profiling of tissue, in lipidomics and proteomic studies.
The ion mobility MSI is suitable for other studies
corresponding to the detection and imaging of large
proteins. Large proteins (80 kDa) are usually difficult
to detect in classical MALDI experiments. The use of
enzymes like trypsin to digest intact proteins offers new
perspectives in the direct on-tissue identification of
these proteins, in frozen as well as formalin-fixed
paraffin-embedded (FFPE) tissue analysis. The conse-
quence of digestion is the increase the number of peaks
in the mass range of 800–3000 m/z. The combination of
ion mobility and MALDI-TOF imaging, in the example
shown in Figure 4, allows the separation of isobaric
peptides and lipids. As such, it combines molecular
imaging with direct identification of many different
peptides in the tissue.
Ion-mobility mass spectrometry generates extra
analytical information used for protein conformer and
nominally isobaric structural identification. The added
value of the IM-MS is the power to selectively isolate
and identify lipids, peptides, and now proteins in a
complex mixture.
1010 HEEREN ET AL. J Am Soc Mass Spectrom 2009, 20, 1006–1014Figure 3. (a) Selected region of the FTICR summed spectrum of half of a rat brain tissue section.
(b) FTICR selected ion images of the first isotope of three different compounds. (c) Region of interest
analysis reveals the spectrum of each individual component. (d) Selected region of the summed spectrum
of half of the rat brain tissue section. (e) The TOF selected ion image of m/z 1294. Because of a technical
problem, a part of a line scan of TOF experiments is not present in the selected ion images.
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Spectrometry
General Sample Preparation and Matrix
Deposition
The quality of the sample surface is the first concern
when performing imaging MS. The surface needs to be
prepared ideally such that the original spatial distribu-
tion of molecules of interest is not compromised. In
addition, imaging MS critically depends on efficient
desorption and ionization of the surface molecules. To
increase the ion yield from biological surfaces or access
specific classes of molecules, surface modifications are
often required. It is important to find tissue treatments
that ensure reproducible and high-quality label-free
molecular images. At this point in time, sample prepa-
ration is one of the most critical steps to obtain high MS
image quality directly from tissue sections. A number of
factors are identified that contribute to this goal: sample
collection and storage, sample pretreatment, surface
coverage with matrix solutions, and methods for matrix
application.
Proper treatment of tissues begins with the surgical
removal of tissue in a manner that avoids possible
delocalization and degradation of the peptides and
proteins. It is beneficial to inactivate enzymes through
denaturation. This prevents the nonspecific degrada-
tion of intact proteins. Freshly harvested/denatured and
frozen samples should subsequently be cryo-sectioned
in thin slices in a contamination-free environment be-
fore the experiments are performed.
A sound washing protocol with various organic
solvents applied to the tissue sections, before the exper-
iments, is the next important step [24]. This procedure
improves the quality of the signal coming from the
tissue sections. The composition of the washing solvent
mixture influences the content of chemical information
obtained from the tissue surface, and each combination
of analysis and tissue washing protocols should be
carefully chosen and optimized for imaging MS exper-
iments. The choice of the matrix solution is the next
essential element of sample pretreatment in imaging
MALDI (and occasionally ME-SIMS) experiments. The
Figure 4. On-tissue identification and repartition of two nomi-
nally isobaric tryptic peptides at m/z 1039 coming from a enzy-
matic digestion of a FFPE rat brain analyzed with MALDI ion
mobility MS imaging.matrix solution should form a homogeneous layer ofmatrix-analyte crystals smaller than the tissue features
that can be observed, given the spatial resolution of the
imaging mass spectrometer used. As for the matrix
choice, along with conventional matrices such as SA,
CHCA, and DHB, also solid/liquid ionic matrices [25]
are demonstrated to be good matrices for imaging MS.
A proper matrix application technique is another
critical element of pretreatment. Aspects such as homo-
geneity of the applied matrix layer and reproducibility
of matrix application to droplet size, speed, surface
wetting, and cost critically determine the matrix depo-
sition method chosen [26]. A high spatial resolution
approach requires the use of small crystals, typically
smaller than the pixel size in the final image. Unfortu-
nately, this often compromises sensitivity because the
extraction capability of smaller droplets is poor. Envi-
ronmental factors such as temperature and humidity
are also important parameters that need to be controlled
during matrix deposition. The deposition of matrix on
tissue that is desiccated while the sample is brought
from80 °C to room temperature for matrix deposition
will result in limited sensitivity. This is a result from the
migration of surface components to the back of the
tissue section when the sample becomes rehydrated
upon first interaction with the matrix solution. When all
these sample preparation requirements are properly
taken into consideration, imaging MS can be reproduc-
ible and routine. Only in that case is it fulfilling the
potential that researchers hope for and can be consid-
ered a powerful new tool for biomedical proteomics.
On-Tissue Digestion and Surface Chemistry
In imaging mass spectrometry the sensitivity for intact
proteins is generally low because of the complexity of
the surface. This results in the generation of images of
only abundant intact proteins such as for instance
histones, myelin, and tubulin in brain tissue. Moreover,
identification of these abundant proteins is complicated
by the post-translational modifications, splice variants,
and different adducts that can be observed. A different
approach is needed to at least partly overcome this
problem. A powerful complementary technique to di-
rect protein analysis is on-tissue enzymatic digestion [5,
26–28]. Protein digestion typically yields peptides be-
tween 400 and 3500 Da, a range in which instrumental
sensitivity is higher than that for intact proteins. How-
ever, the mass spectrum is more complicated in the
low-mass region. In addition, enzymatic digestion en-
ables efficient MS/MS on small singly charged peptides
in ToF-based instruments. Current approaches for iden-
tification of digested proteins or peptides from tissue
involve extraction and separate MS/MS measurements,
sometimes followed by comparison with on-tissue pep-
tide mass fingerprinting (PMF) [26]. Tissue chemical
complexity prohibits efficient PMF. Further, the mass-
resolving power and mass accuracy of ToF instruments
are usually insufficient for exact mass detection of all
measured intact proteins, although FT-ICR MS and
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earlier [15]. MS/MS has scarcely been performed di-
rectly on tissue—typically on the most abundant pep-
tides [27] or to distinguish between isobaric compounds
rather than absolute identification [29, 30]. However,
the chemical complexity on tissue may cause multiple
peptides at each nominal mass. As a consequence,
except for higher abundant peptides, identification by
MS/MS may prove difficult as a result of the fragments
from different peptides. To overcome this issue chemi-
cal derivatization of the peptides combined with a
post-ionization strategy could enhance the identifica-
tion capabilities for these types of studies [31]. The
enhanced sequencing capabilities using MS/MS offered
by the application of tri-methoxyphenylphosphonium
(TMPP) derivatives [32] on digested tissue surfaces is a
potential alternative method to overcome the identifi-
cation sensitivity issues. From an instrumental perspec-
tive ultrahigh resolution FT-ICR MS imaging or gas-
phase ion mobility separation before MS/MS can assist
in tryptic peptide identification.
These on-tissue digestion and derivatization proto-
cols involve liquid handling and the deposition of large
droplets (typically, 100 m in diameter) using robotic
deposition methods. Once again, great care has to be
taken to control temperature, surface salt content, and
humidity during the digestion process. All spatial in-
formation within the droplets is lost during the diges-
tion process. On-tissue digestion is therefore mostly
suited for use in combination with lower-resolution
techniques. New digestion protocols are continuously
being developed that can also be used for MALDI
imaging MS [33].
Challenge the Picture: Ion Suppression
Does a measured image quantitatively reflect the vari-
ation in concentration of a specific molecule? In other
words: what is the value of a mass-resolved image? This
is a question that is very difficult to answer as a result
of the ion-suppression effect. Ion suppression is a term
that refers to the fact that surface ionization processes
do not result in identical ionization efficiencies for each
chemical species on the surface. The ionization effi-
ciency and thus the analyte intensities depend on the
local chemical environment [34]. This makes it nearly
impossible to generate quantitative mass spectrometric
images without evaluating the ion-suppression effects
for the compounds of interest on the tissue under study.
This applies both for SIMS [35] and MALDI-MS molec-
ular imaging. The best example is given by the compar-
ison between a gradient of matrix-to-analyte ratio on a
surface and in the resulting mass spectra [36]. Specific
ionization yields in MALDI are hard to predict because
they are the result of numerous equilibria [37, 38] that
are influenced by a high degree of chemical complexity
of biological tissues.
The ion-suppression effect is a major obstacle to
quantification in many analytical disciplines. The inter-pretation of mass spectrometric images is intrinsically
quantitative, which confers an added importance to this
phenomenon. The MS image of a biological surface
appears to display the differential relative concentration
between analytes, which is precisely the result we want
to observe. Here we run into a chicken-and-egg prob-
lem. We want to observe the spatial distribution of
molecules, yet the spatial distribution of these mole-
cules can influence the outcome of the experiment.
Figure 5 illustrates the effect of a different chemical
environment on the resulting mass spectra: three aque-
ous protein digest solutions (bovine serum albumin
[BSA], cytochrome C, and ubiquitine) are spotted two
by two in identical concentrations with a saturated
matrix solution of HCCA in water:acetonitrile (30:70
and TFA 0.1%). Images are acquired by MALDI-ToF
imaging with an ULTRAFLEX-III (Bruker Daltonik
GmbH, Bremen, Germany) using the associated Bruker
FlexImaging software. Specific images are produced by
selection of peaks specific for each of the protein
digests. Although cytochrome C and ubiquitine appear
simultaneously, they do not show up where BSA was
spotted, illustrating a strong suppression of BSA digest
on both of the other peaks.
Considering the potential impact on the interpreta-
tion of a mass image, sample preparation protocols
need to be adapted to limit the effect of ion suppression.
To counteract the ion-suppression effect of salts, wash-
ing the tissue with polar solvent is very commonly
performed (see sample preparation). Lipid removal,
used for peptides and protein imaging, is done by
washing tissue with apolar solvents like chloroform
[24]. In some cases it is possible to foresee the potential
importance of the ion-suppression effect on a tissue of
interest by homogeneously covering a test tissue section
with known standard compound with a chemical struc-
ture similar to that of the analytes under study. A wide
range of chemical environments are expected from
different cell types on a single tissue section (e.g.,
stroma versus epithelial cells or gray versus white
matter in brain). In some cases it is observed that there
is no important ionization difference if the cell types are
Figure 5. MS image of peptides identified by MS/MS from
digests of BSA (red), ubiquitin (green) and cytochrome C (blue).
BSA completely suppresses the signal from the 2 other protein
digests.sufficiently similar and the main difference remains
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tissue [26]. This implies that in spite of ion-suppression
effects for selected compounds and selected tissues it is
possible to perform relative quantitation.
Summary
Clearly, great care has to be taken when interpreting
mass spectral images. The mere display of single mass
images revealing an anatomical feature on tissue is
slowly making way for interpreted images of identi-
fied endogenous biomolecules or pharmaceutical com-
pounds. Imaging mass spectrometry has developed to a
technique that can solve actual problems in biomedical
research. Yet it has its limitations. Instrumentation
developments for imaging MS are continuously remov-
ing technical barriers and limitations and result in an
increase of its analytical value. Each implementation of
imaging MS can visualize a small subset of all mole-
cules present on the surface under study. Each imple-
mentation offers different sensitivities, spatial res-
olution, and speed of analysis. All MS imaging
implementations need to be combined with other mo-
lecular imaging techniques and standard analytical
protocols applied to tissue homogenates to provide
positive identification of the molecules associated with
a spatial structure. If researchers who move into this
field take this and the effects of sample treatment/
handling into account then the technique is past the
hype stage and is fulfilling its full potential. In the
future we will see multiple new applications develop-
ing in the field of nanomedicine, pharmacokinetics,
proteome imaging, and many others. It will take at least
another 5 years to firmly state that the applications of
imaging mass spectrometry have fulfilled the hope of
the researchers in these fields. There is still a lot of work
to be done—when you look at it critically!
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